Related Experiment Videos

Challenging paradigms in lymphoma treatment

M Bendandi¹, S A Pileri, P L Zinzani

¹Department of Hematology and Cell Therapy Area, University Clinic, University of Navarra, Avda. Pio XII 36, 31008 Pamplona, Spain. mbendandi@unav.es

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|April 28, 2004

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.

ESMO open·2026

Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.

British journal of haematology·2024

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

The importance of assessing blood tumour burden in cutaneous T-cell lymphoma.

The British journal of dermatology·2020

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Blood cancer journal·2019

See all related articles